WASHINGTON - A Medicare advisory panel Wednesday said evidence backed the use of Amgen Inc.'s Epogen (epoetin alfa) and Aranesp (darbepoetin alfa) and Centocor Ortho Biotech Products LP's Procrit (epoetin alfa) as therapies to manage anemia in dialysis patients with chronic end-stage renal disease (ESRD). (BioWorld Today)